GU Cancers 2025 | Efficacy and toxicity considerations when selecting patients for ADCs
Terence Friedlander, MD, University of California, San Francisco, CA, highlights key factors physicians must consider when selecting patients for antibody-drug conjugates (ADCs) like enfortumab vedotin (EV) and pembrolizumab. Dr Friedlander discusses the efficacy of these drugs compared to standard chemotherapy, as well as potential toxicities, including neuropathy and skin reaction. He also explores the importance of dose adjustments, monitoring, and educating patients and caregivers to manage side effects effectively. Careful patient selection is vital to ensure the best therapeutic outcomes without causing debilitating side effects. This interview took place at the ASCO GU Cancers Symposium 2025 in San Francisco, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
